IRIX Stock Analysis: Buy, Sell, or Hold?
IRIX - Iridex Corp
$1.13
-0.04 (-3.42%)
▼
5d:
-4.24%
30d:
-3.42%
90d:
+19.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When IRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IRIX shows positive signals but monitor for confirmation. Market pricing in 0.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: IRIX shows positive signals but monitor for confirmation. Market pricing in 0.1% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IRIX is currently trading at $1.13, which is considered fair relative to its 30-day fair value range of $1.08 to $1.18. The stock's valuation (Forward PE: 56.5) is in line with its historical norms (56.3). At these levels, the market is pricing in 0.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IRIX is in a strong downtrend. Immediate support is located at $1.01, while resistance sits at $1.20. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.75 (+143.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRIX is in a strong downtrend. Immediate support is located at $1.01, while resistance sits at $1.20. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.75 (+143.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.08 -
$1.18
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 143.4% below Wall St target ($2.75)
- NEUTRAL: Market pricing in 0.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.01
Resistance Level
$1.20
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
56.50
Wall Street Target
$2.75
(+143.4%)
Revenue Growth (YoY)
-0.8%
Profit Margin
-6.2%
Valuation Premium vs History
+0.1% premium
PE vs Historical
56.5 vs 56.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.1%
(market-implied from PE analysis)
1-Year Target
$1.13
(+0%)
2-Year Target
$1.13
(+0%)
3-Year Target
$1.13
(+0%)
3-Yr Target (if PE normalizes)
(PE: 57→56)
PE COMPRESSION
$1.13
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 03, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
